Argenx (ARGX) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Argenx (ARGX) has completed a Phase 4 study called “A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC.” The goal was to see how adults with chronic inflammatory demyelinating polyneuropathy move from standard IV immunoglobulin to a newer under-the-skin option, and what this could mean for real-world use and long term care.
The treatment tested is efgartigimod PH20 SC, a biological drug given as a subcutaneous injection. It is designed to replace or reduce the need for IVIg in CIDP, aiming for similar disease control with a more convenient and potentially less resource heavy dosing method.
The trial used a simple, open label, single group design where all enrolled patients switched from IVIg to efgartigimod PH20 SC. There was no randomization or placebo, and the main purpose was treatment focused, looking at how well patients tolerated the switch and how stable their condition remained over the study period.
The study started enrolling in October 2024 and followed each participant for about 17 to 19 weeks, giving a short to medium term view of the switch. The trial was marked as completed and the most recent update was submitted on April 3, 2026, signaling that final data are locked and ready for deeper analysis or publication.
For investors, this update reinforces Argenx’s effort to extend efgartigimod beyond myasthenia gravis into CIDP and other antibody driven diseases. Positive real world style Phase 4 data could support stronger uptake, sharpen pricing power versus IVIg providers, and pressure rivals in neuromuscular and autoimmune segments, though the exact stock impact will depend on the strength of the efficacy and safety signals once disclosed.
The study is now completed and recently updated, with additional information and any forthcoming results to be made available through the ClinicalTrials portal.
To learn more about ARGX’s potential, visit the Argenx drug pipeline page.